Alex Waterson
-
Vanderbilt-discovered cancer killing compound is now available through Boehringer Ingelheim open science portal opnMe
Researchers in the lab of Stephen Fesik, Orrin H. Ingram II Chair in Cancer Research, have added BI-0474 as the second molecule co-discovered by Vanderbilt to the open science portal opnMe.com, an initiative being driven by biopharmaceutical company Boehringer Ingelheim. Read MoreMay 30, 2024
-
Professor makes Vanderbilt-discovered cancer targeting molecule freely available to researchers through collaboration with Boehringer Ingelheim
Stephen Fesik’s discovery of a cancer-targeting molecule has been made freely accessible through opnMe for global researchers to advance research into cancer therapeutics. Read MoreNov 15, 2021
-
VU takes key role in cancer drug discovery consortium
Vanderbilt University has been selected as one of seven Dedicated Centers in the nation for the next phase of the Chemical Biology Consortium (CBC), a national network of scientists on the leading edge of cancer drug discovery. Read MoreJun 23, 2016